| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
| |
|
|
| |
 |
|
| |
 |
|
 |
|
|
| |
|
| Professor Dominic LAM
was born in Swatow, China and received his early education in Hong
Kong. He received his BSc in mathematics from Lakehead University
in 1967, his MSc in theoretical physics from the University of British
Columbia in 1968 and his Ph.D. in medical biophysics from the University
of Toronto in 1970. Professor Lam was a faculty member at the Harvard
Medical School and the Baylor College of Medicine in the 80’s
and he was also the Chairman of Houston Biotechnology Incorporation
at the same period. |
| |
| Professor LAM has published
more than 180 scientific papers and abstracts. His research interest
and publications are mainly in the areas of molecular mechanisms underlying
neuronal communication in general, and the processing of |
| visual information
in particular. The vertebrate retina has been his model system for
such studies. His research focus was on the use of transmitters and
neuropeptides as physiological probes to study the organization and
development of the retina. He was appointed the first Managing Director
of HKIB in 1988. |
| |
|
|
| |
|
|
| |
| |
|
|
| |
 |
|
| |
 |
|
 |
|
| |
|
| Professor Kin-ping WONG
received his Bachelor degree in Chemistry from the University of California,
Berkeley in 1964 and his Ph.D. in Physical Chemistry and Biochemistry
from Prudue University in 1968. After being a postdoctoral fellow
in Duke University Medical Center, he traveled to Germany and Sweden
and began his scientific career as a Visiting Scientist and Senior
Fellow there. He held important positions in different professional
associations and major U.S. universities. First as a Research Associate
at Duke University, then as Assistant and Associate Professor at University
of South Florida, and subsequently Associate, Full Professor, and
Dean of Graduate Studies at University of Kansas. Before his appointment
as Director of HKIB in 1993, he was the Dean and |
| Professor at the California State
University, Fresno and Adjunct Professor of Medicine and Biochemistry
and Biophysics at the University of California San Francisco. |
| |
| Dr. Wong carried out extensive research
in Biochemistry and Molecular Biology. His fields of studies include
the biochemistry of proteins, the molecular basis of cancer and protein
candidates for cancer therapy, the folding and stability of RNA and
more recently the molecular biology of angiogenesis and its inhibitors.
Professor Wong has published more than 80 conference papers and research
articles as well as 2 major science textbooks. He has secured a total
of 12 U.S. Patents on his work in angiogenesis inhibitors. |
| |
| |
| |
| |
|
|
| |
 |
|
| |
 |
|
 |
|
|
| |
|
| Dr. Albert CHANG
received his BSc degree from the National Taiwan University in 1958
and the MSc degree from the University of California, Berkeley in
1962. After he obtained his Ph.D. in Biochemistry at the University
of Illinois, he continued to work as a post-doctoral fellow in the
Virus Laboratory of the same university up to 1967. From 1967 to 1993,
Dr. Chang developed his career in the pharmaceutical industry in the
Upjohn Company where he first held the position of a Research Scientist
and later became a senior administrator holding the position of Research
Head, AssociateDirector, Strategic Planning and International Liaison
Director of Pharmaceutical Research and finally the International
Liaison Director in 1990. |
| |
| While at the Upjohn Company, Dr.
Chang led a number of projects on the discovery and development of
new therapy for diabetes mellitus and on defining the marketing strategy
of anti-diabetic products. The development of ciglitazone, a breakthrough
oral hypoglycemic drug candidate for non-insulin-dependent diabetes
mellitus (NIDDM) patients, in collaboration with Takeda Chemical Industry
of Japan, was a milestone of Upjohn as well as Dr. Chang’s statuein
pharmaceutical research. |
| |
| Apart from his professional positions
in the Upjohn Company, Dr. Chang was an active scientistand scholar
holding a number of ancillary positions in the United States, Taiwan,
and China. He has published more than 100 scientific papers in peer-reviewed
journals, book chapters, and conference papers. And he has also been
invited to lecture in universities and biotechnology conferences in
different countries. He himself also organized a number of workshops
and symposia related to diabetes research and biotechnology since
1974. |
| |
| Dr. Albert Chang took up his Directorship
of our institute from 1994 to 1999 after he has been the Managing
Director of Pharmaceutical R&D Laboratories, Development Centre
for Biotechnology, Taiwan for 3 years. Under his leadership our institute
has grown tremendously in the past ten years and now it is recognized
as a key organization in Chinese medicine development and biotechnology
in Hong Kong. |
| |
|
|
| |
|
|
| |
| |
|
|
| |
 |
|
| |
 |
|
 |
|
| |
| Dr. Shawn LEUNG
received his BSc in Biochemistry and M. Phil.degrees from the Chinese
University of Hong Kong in 1984 and 1986, respectively. He finished
his Ph.D. in Molecular Biology from the University of Oxford, England
in 1989, and his research was focused on studying the transcription
and translation of the human q-globulin gene. Subsequently, he joined
the Yale University as a postdoctoral fellow and worked in the field
of immunobiology until he took the position as Associate Director,
Division of Molecular Biology Immunomedics, Inc., New Jersey. Later
he became the Director and the Executive Director in Biology Research
of Immunomedics. In 2000, Dr. Leung took up the position as the Managing
Director of the Hong Kong Institute of Biotechnology where he stayed
until the end of 2002. |
| |
| Dr. Leung’s research interest
was in cancer research and the immune system. He has published a large
number of papers in peer-reviewed journals such as Nature, Clinical
Cancer Research, Hybridoma, Cancer Research, Molecular Immunology,
Journal of Immunology, International Journal of Cancer,
and Immunopharmacology. He has won a number of research grants
from the National Institutes of Health and the National Cancer Institute
in the study of immunology and cancer. His work on immunoconjugates
and antibody for clinical therapy has resulted in 13 US Patents. Dr.
Leung has contributed significantly to
the field of immunotherapy using monoclonal antibodies. |
| |
|
|
| |
|
|
| |
| |
|
|
| |
 |
|
| |
 |
|
 |
|
| |
| Professor Walter
HO is presently the Professor of the Department of Biochemistry
in the Chinese University of Hong Kong and the Managing Director of
the Hong Kong Institute of Biotechnology. He obtained his undergraduate
degree in Biochemistry and Economics and Ph.D. degree in Biophysics
from the University of California, Berkeley. |
| |
| Professor HO actively
participates in the promotion of biotechnology in Hong Kong. From
1995 to 1999, he was a member of the Biotechnology Committee under
the Hong Kong Government Industry Department. He is also a founding
and council member of the Hong Kong Biotechnology Association. In
addition, he has organized a number of conferences and |
| workshops
in various biotechnology topics. Professor HO is currently honorary
professor of the Guangzhou Medical University and Zhejiang Academy
of Agricultural Sciences in China and he has also acted as consultants
to a number of biotechnology companies in Hong Kong. |
| |
|
|
| |
| |
